<DOC>
	<DOCNO>NCT00712062</DOCNO>
	<brief_summary>The purpose study determine pemetrexed effective treatment primary central nervous system lymphoma ( PCNSL ) either worsen treatment return complete treatment .</brief_summary>
	<brief_title>Study Pemetrexed Treat Recurrent Progressive Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>Despite aggressive upfront use methotrexate-based chemotherapy , primary central nervous system lymphoma ( PCNSL ) almost uniformly result recurrence progression death . Palliative chemotherapy offer improvement time-to-progression , symptom control , quality life , potentially , survival . However , establish chemotherapy regimen recurrence exist new treatment need . Pemetrexed rationale strategy therapeutic palliation recurrent progressive PCNSL , give mechanism action , convenient administration , single agent efficacy , well establish management algorithm , evidence safety efficacy systemic malignancy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological confirmation Primary Central Nervous System Lymphoma Male female &gt; 18 year age older Negative pregnancy test ( childbearing potential ) Any number previous recurrence allow Karnofsky Performance Status &gt; 60 Hematocrit &gt; 30,000 Platelet &gt; 100,000 Absolute Neutrophil Count &gt; 1,500 Bilirubin &lt; 1.5 x upper limit normal Transaminases ( ALT AST ) &lt; 1.5 x upper limit normal Creatinine &lt; 1.5 x upper limit normal Creatinine Clearance &gt; 45 mL/min Adequate medical health participate study Adequate documentation menopause ( natural/surgical ) patient commitment routine use reliable birth control ( barrier/hormonal ) Ability read understand patient inform consent form Ability willingness follow requirement study include follow direction , take medication prescribe , completion diary form Karnofsky Performance Status &lt; 60 Hematocrit &lt; 30,000 Platelet &lt; 100,000 Absolute Neutrophil Count &lt; 1,500 Bilirubin &gt; 1.5 x upper limit normal Transaminases ( ALT &amp; AST ) &gt; 1.5 x upper limit normal Creatinine &gt; 1.5 x upper limit normal Creatinine Clearance &lt; 45 mL/min Inability undergo gadoliniumcontrasted MRIs , include severe claustrophobia insufficient allergy prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>PCNSL</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Alimta</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Progressive</keyword>
</DOC>